APOB and metabolic dysfunction-associated steatotic liver disease: Compared to controls, APOB carriers had higher steatosis grade (2.4 vs. 1.7, p‐value 0.0028), higher NAFLD activity score (NAS) (4.9 vs. 3.8, p‐value 0.04), and numerically higher but statistically not significant fibrosis stage (1.2 vs. 1.1, p‐value 0.75) and ALT (87.4 vs. 58.1 U/L, p‐value 0.06).